Purpose: The aim of this pooled analysis was to evaluate the clinical efficacy and safety of transarterial radioembolization (TARE) with yttrium-90 ( 90 Y) microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma (ICC). Methods: We searched the Cochrane Library, Embase, PubMed, SCI with the English language from inception to October 2018. A pooled analysis was conducted using Stata software.
Introduction
Intrahepatic cholangiocarcinoma (ICC) is a highly invasive malignancy of the biliary tract with high mortality due to its infiltrative nature, propensity for advanced disease presentation and resistance to chemotherapy. 1, 2 From diagnosis, the median overall survival (OS) of ICC without treatment is about 4.5 months. Surgical resection may be the only potentially curative treatment, however, only 30-40% of ICC patients are the surgical candidate when the diagnosis is first confirmed. 3, 4 Systemic chemotherapy with cisplatin plus gemcitabine is also limited by poor response rates. 5, 6 Transarterial radioembolization (TARE) with yttrium-90 ( 90 Y)-labeled glass or resin microspheres are being used increasingly in primary and secondary liver malignancies, which provides an advantage to the median OS with good tolerance. 7 
Material and methods

Search strategy
We searched the Cochrane Library, Embase, PubMed, SCI with English language from inception to October 2018. Relevant documents were supplemented by references of retrieved articles. The terms we used to search were related to intrahepatic cholangiocarcinoma, intrahepatic bile duct carcinoma, cholangiocellular carcinoma, neoplasms of the biliary tract, cholangiohepatoma, yttrium-90, Y90, 90 Y, SIR-Spheres, TheraSphere, radiation lobectomy. Inclusion and exclusion criteria The quality of the studies was independently evaluated by two reviewers based on the Downs and Black quality assessment checklist. 10 
Data extraction
Two authors extracted the data and a third one resolved any disagreements. The extracted data included details of type of researches (prospective or retrospective cohort), number of patients, age, sex, Eastern Cooperative Oncology Group (ECOG) score, extrahepatic metastases, pre-and postchemotherapy, type of microspheres, dosimetric calculation, follow-up time, median OS, 1-year survival, evaluation criteria, tumor response, side effects (eg clinical toxicities such as fatigue, abdominal pain, nausea, and biochemical toxicities such as decreased albumin, elevated bilirubin, alkaline phosphatase, etc).
Statistical analysis
Only median OS and disease control rate (DCR) were pooled analysis by Stata 11.0 (StataCorp. 2009. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP.), while other outcomes were analyzed in descriptive statistics. The I 2 measure was used to show the inconsistency between studies. An Egger test was used to assess publication bias, and Metaninf was used for sensitivity analysis, a two-sided P<0.05 was regarded as significant.
Results
According to the inclusion and exclusion criteria, 16 eligible studies [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] were identified that reported the TARE with 90 Y microspheres for unresectable ICC (Figure 1 ). Five prospective and 11 retrospective studies were included. There were 472 patients included in this pooled analysis. Patient characteristics were presented in Table 1 Side effects and the proportion of grade III-IV toxicities were listed in Table 3 Mild and moderate heterogeneity was shown in pooled median OS and DCR. These estimates were robust in the sensitivity analysis. No significant publication bias was identified in pooled analysis.
Discussion
The pooled analysis showed that TARE with 90 Y microspheres can be an effective treatment for unresectable ICC with a pooled median OS of 14.3 (95%CI:
12.0-17.1) months. According to RECIST, the pooled DCR was 77.2% (95%CI: 70.2-84.2%). Subgroup analysis was conducted by microsphere type, it seems that there were similar median OS and DCR in the glass and resin microspheres group. In addition, it was associated with mild clinical and biochemical toxicities, and often these symptoms were relieved over time.
With the increasing incidence of ICC and impossibility of surgical resection, more and more people are exploring new treatments. TARE with Y radioembolization. However, seven abstracts were included in the pooled analysis, which provided limited information regarding treatment and follow-up outcomes. In the current pooled analysis, we excluded abstracts and added literature published in recent years, which provided more comprehensive information. We came to a similar median OS of 14.3 months. Subgroup analysis was performed based on the type of microspheres, and the median OS was similar in the resin and glass microspheres groups (14.0 vs 14.3 months). Unfortunately, due to the heterogeneity of studies in each group, the random effects model was performed, which failed to compare the differences between groups. Nezami et al 28 compared the dose of 25 Rafi et al (2013) 24 Hoffmann et al (2012) 22 Jia et al (2017) 21 Soydal et al (2016) 20 Paprottka et al (2017) 16 Gangi et al (2018) 13 Filippi et al (2015) 11 Beuzit et al (2016) 12 Shaker et al (2018) 14 Camacho et al (2014) 15 Swinburne et al (2017) 
Pooled analysis of disease control rate DCR (95%Cl) Weight (%) Study
Saxena et al (2010) 26 Mosconi et al (2016) 25 Rafi et al (2013) 24 Hoffmann et al (2012) 22 Gangi et al (2018) 13 Beuzit et al (2016) 12 Reimer et al (2018) 18 Camacho et al (2014) 15 Swinburne et al (2017) 19 Overall (I-squared=50.7%, P=0.039) Y microspheres was generally consistent with TACE. However, further randomized controlled trials are needed to confirm these results.
In the current pooled analysis, most of the studies (11/16) evaluated tumor response according to RECIST, and the pooled DCR was 77.2%, which indicated that TARE was an effective treatment for ICC. However TARE with 90 Y microspheres usually leads to necrosis without an actual decrease of tumor size, RECIST 31, 32 only considers the change in the size of target lesions, and the association between RECIST and survival still needs further to be investigated. PET can evaluate the change of tumor volume through the difference of standardized uptake value, which is valuable in assessing the activity of cancer therapies that stabilize diseases. 33 Zerizer et al 34 reported that 18F-FDG PET-CT was superior to RECIST in evaluating early response of TARE and predicting progression free survival in patients with liver metastases. Therefore, PET-based approaches are expected to be effective evaluation criteria in tumor response after TARE with 90 Y microspheres. In addition, TARE with 90 Y microspheres is associated with some side effects. In the current pooled analysis, the common clinical toxicities mainly included fatigue, abdominal pain, nausea, vomiting, ascites, and biochemical toxicities had decreased albumin, elevated bilirubin and alkaline phosphatase, etc. These side effects were usually mild and acceptable, and could be resolved without medical therapy. Moreover, gastroduodenal ulceration is a relatively common serious side effect of TARE with -90 Y microspheres, 35 which is caused by nontargeted microsphere distribution, so it is necessary to clarify the vascular anatomy and undergo prophylactic arterial embolization; in addition, microspheres must be carefully injected during the treatment process to avoid nontargeted embolization.
There are several limitations in the current pooled analysis. First, in the pooled analysis, not all studies reported the population and treatment characteristics that were meta-analyzed, thus not allowing a complete analysis of heterogeneity sources. Second, meta-regression was not performed in the current analysis because the pooled results were robust in the sensitivity analysis, which suggested the source of heterogeneity may not exist in studies, but in individuals. Third, side effects were summarized only as descriptive words, standardized methodology needs to be used. Fourth, the current results failed to help define the best population for TARE, but this pooled analysis included the best available evidence and provided valuable information on the therapeutic efficacy and safety of TARE with 90 Y microspheres for unresectable ICC.
Conclusion
TARE with
90
Y microspheres is a promising therapeutic option for patients with unresectable ICC with acceptable side effects. The different microspheres seem to have no influence on therapeutic efficacy, and TARE with 90 Y microspheres has a similar OS compared with TACE reported in previous studies. A large sample of randomized controlled trial is warranted to confirm the above results.
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